相关实验视频
Updated: Jun 30, 2026

Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
美国指导的二次性偏甲状腺症的皮肤间射频消去:长期结果和预后因素
Wenwen Yue1, Tingting Jiang1, Zisheng Ai1
1From the Center of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, No. 301 Yanchang Zhong Road, Jingan District, Shanghai 200072, China (W.Y., T.J., E.D., H.C., L.S., C.P.); Shanghai Engineering Research Center of Ultrasound Diagnosis and Treatment, National Clinical Research Center for Interventional Medicine, Shanghai, China (W.Y., T.J., E.D., H.C., L.S., C.P.); Department of Medical Statistics, School of Medicine, Tongji University, Shanghai, China (Z.A.); Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China (X.L., H.X.); Department of Ultrasound, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China (H.H.); Departments of Ultrasound (Z.Z.) and Nephrology (N.W.), Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China; Department of Ultrasound, The First Affiliated Hospital of Anhui Medical University, Hefei, China (X.Q.); Department of Ultrasound, Nanchong Central Hospital, North Sichuan Medical College, Nanchong, China (X.Q.); Department of Ultrasound, Yiwu Fuyuan Hospital, Yiwu, China (J.F., X.T.); and Departments of Ultrasound (W.H.) and Nephrology (Y.L.), The First People's Hospital of Aksu, Xinjiang, China.
射频切除 (RFA) 提供了一种安全有效的长期治疗二次性偏甲状腺症 (SHPT) 在透析患者. 治疗不到四个腺体可能会预测治疗失败.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 干预性放射学 干预性放射学
背景情况:
- 二次性偏甲状腺症 (SHPT) 是透析患者的常见并发症.
- 射频剥离 (RFA) 对SHPT有希望,但长期数据有限.
研究的目的:
- 评估在透析患者中对SHPT进行超声导向皮肤通用RFA的长期疗效和安全性.
- 为了确定治疗失败的预测因素.
主要方法:
- 在七个中心对165名SHPT透析患者进行RFA治疗的回顾性研究 (2013年5月至2022年7月).
- 主要终点:副甲状腺激素 (PTH) 水平在随访时≤585 pg/mL (平均51个月).
- 二级终点包括正常的/,技术成功,并发症和症状改善.
主要成果:
- 在78.2%的患者中,RFA实现了目标PTH水平,技术成功率为100%.
- 观察到PTH,,和与甲状腺功能障碍相关的症状显著减少.
- 常见的并发症是低血症 (45.8%);36名患者出现治疗失败,预测的治疗腺体少于四个.
结论:
- 超声导向皮肤透射RFA是一种安全有效的长期非手术选择,用于透析患者的SHPT.
- 治疗腺体的数量 (<4) 是治疗失败的潜在独立预测指标.
相关概念视频
Chronic Pancreatitis II: Collaborative Care
Assessment:
Acne Infection

